Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical
cannabis company, is reviewing interim results of its survey from over
1400 people, US military veterans and others who responded to our PTSD
survey. The survey is still available for a limited time online on the www.cannabisscience.com
website for all those who still wish to participate.
The survey was designed and conducted by Mitch Earleywine, Ph.D.
Professor of Psychology at the State University of New York (Albany). Dr
Earleywine is also a member of the Cannabis Science Inc. Scientific
Advisory Board. The survey results will be made public as soon as the
study has been completed.
Dr. Robert Melamede, Cannabis Science President and CEO, observed, "It
is clear that many veterans are already using herbal cannabis to
self-medicate to relieve the symptoms of PTSD. Consequently, there is a
clear need for standardized, FDA approved, oral cannabis products which
can, and should be, provided to veterans and others who can benefit from
its use. Medical cannabis has far fewer and milder side effects than
most currently prescribed pharmaceutical products do. We are working
hard to have one or more products ready for FDA clinical trials as soon
as possible."